MENDOZA MILLA, CRISELDA

MENDOZA MILLA, CRISELDA

MEDICINA Y CIENCIAS DE LA SALUD · Nivel 1

Signal transduction Cell biology

Desde 2003 es PI en Instituto Nacional de Enfermedades Respiratorias

Información*

Nombre CRISELDA MENDOZA MILLA
Área MEDICINA Y CIENCIAS DE LA SALUD
Campo MEDICINA Y CIENCIAS DE LA SALUD
Disciplina OTRAS ESPECIALIDADES MÉDICAS
Especialidad OTRAS
CVU 75092
Institución
Dependencia SIN INFORMACIÓN
Entidad CIUDAD DE MEXICO
Nivel 1
Vigencia Inicio: 01/01/2025
Fin: 31/12/2029

* Información del primer trimestre de 2026.
Fuente: SECIHTI.

Publicaciones ORCID

2024
Time-Course and Fraction Analysis in Western Blot Reveals Improved Approaches for Evaluating Neutrophil Extracellular Trap-Associated Proteins
2022
Zinc Oxide Nanoparticles Induce Toxicity in H9c2 Rat Cardiomyoblasts International Journal of Molecular Sciences
Differential Leukocyte Expression of <i>IFITM1</i> and <i>IFITM3</i> in Patients with Severe Pandemic Influenza A(H1N1) and COVID-19 Journal of Interferon & Cytokine Research
Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer European Journal of Cancer
2021
Mitochondrial Dysfunction and Alterations in Mitochondrial Permeability Transition Pore (mPTP) Contribute to Apoptosis Resistance in Idiopathic Pulmonary Fibrosis Fibroblasts International Journal of Molecular Sciences
Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019 The Journal of Infectious Diseases
Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1) Frontiers in Immunology
LncRNA SOX2‐OT regulates AKT/ERK and SOX2/GLI‐1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases Molecular Oncology
Mesenchymal–Epithelial Transition in Fibroblasts of Human Normal Lungs and Interstitial Lung Diseases Biomolecules
CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome Frontiers in Immunology